TrialCancer medicine2013

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.

Andres Forero-Torres et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.